Among patients with advanced gastrointestinal stromal tumors, Gleevec and Mektovi was associated with benefits in progression and survival.

HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and executed. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, HopeAI ...

The risk was particularly high in men (21 per cent increase versus nine per cent in women) and in under-60s (24 per cent ...

More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) ...